Drug Pricing

A White House push for direct-to-consumer drug sales could benefit companies linked to Trump’s son and cabinet members’ families.

Moneycontrol Selects National Edition: Top stories this morning

Our specially curated national news edition to help you stay at the top of your game.

Will rise in price caps of essential drugs expose chinks in price control policy?

Advocates of patients’ rights say the increases undermine the purpose of setting prices of essential medicines and wholesale inflation may not be the most appropriate basis.

Commonly used medicines to get 12% more expensive from April

Prices of non-scheduled drugs, on the other hand, are set to go up by up to 10 percent as per government rules.

Economic Survey 2023: Govt keeping check on drug prices through direct price control, Janaushadhi stores

Strap: In the report, measures by the government that are adopted to make medicines affordable for the citizens, have been mentioned

NSE-listed ZIM Laboratories eyes nutraceutical segment, regulated markets abroad

The company has developed a portfolio of innovative and differentiated generic drug delivery products, which are at an advanced stage of filing in the European Union and emerging markets.

Doctors’ body pitches for capping trade margin at 30% for all drugs in India

The demand, aimed at bringing relief to patients, comes at a time when the government is already considering limiting profit margins for a large number of commonly used medicines

Doctor-Pharma Nexus Part II: What drives drug prescription in India?

If doctors are concerned about the quality of generic drugs and hesitate to prescribe them, how do they decide which medicines patients should take?

Pharma-Doctor Nexus Part I: Why rules, Code for doctors, drugmakers have failed to curb unethical practices

The Medical Council of India's (now Medical Commission of India's) rules for doctors and the Uniform Code of Pharmaceutical Marketing Practices have elaborate guidelines to curb such practices, but with no real statutory backing they remain on paper even as the patients suffer. 

Regulator fixes retails prices of 45 drugs, many of them drug cocktails

Last month, the drug price regulator had fixed the prices of 84 drug formulations

Regulator fixes retail prices of 15 anti-diabetic formulations

In October last year too, the pharma pricing regulator had fixed the retail prices of 12 formulations used in diabetes management

Explainer I How the drug price regulator’s order raising the cap on prices of essential medicines by 10.7% may hit you 

Activists point that as the current drug pricing regime does not cover essential drugs in all their strengths and presentation, patients lose out on many counts

Retail prices of common medicines set to rise by a steep 11%

Industry insiders say that this will be the steepest ever rise in medicines included in the National List of Essential Medicines.

Pharma: Trump’s executive orders may possibly provide better market access opportunities

Indian drugmakers such as Cipla, Cadila, Lupin, Dr Reddy’s, Sun Pharma and a few small-sized pharma companies such as Laurus Labs may benefit from a likely revamp of US medicare

Pharma Weekly: Martin Shkreli goes to jail but his career holds lessons for India

Inflated margins and price gouging are quite prevalent in Indian private healthcare market.

Put price cap on medicines, hip & knee implants: Doctors to PM

Hailing the Centre's decision to put a cap on prices of coronary stents, a group of doctors today sought a similar cap on the prices of medicines, hip and knee implants and intraocular lenses.

Stents pricing: Govt asks hospitals to make prompt refunds

No action will be taken against hospitals under the scanner for overcharging on stents if they refund the money to patients before receiving a demand notice, drug price regulator NPPA said.

GlaxoSmithKline Pharma Q3 profit dips 33% to Rs 53 cr

The company said mandatory price reductions experienced in the earlier quarters of the year had adversely impacted growth by 5 percent in the current quarter.

No scope of US intervention in Indian pharma cos: Wockhardt

Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.

Expect drug pricing pressure to continue in next few years: GSK

The US market is seeing a shift in market dynamics and several factors lead to drug product pricing and there will be further pricing pressure over the next few years, said GSK Global Chief Executive Andrew Witty.

Centre's new drug pricing policy comes under SC scanner

Agreeing to examine the validity of policy, the apex court sought response from Centre on a PIL alleging that the new policy would result in increase of prices of essential and non-essential drugs.

NPPA to fix cap on prices of over 300 drugs by month-end

Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) said that it will fix the ceiling prices of over 300 formulation-based drugs by the month-end.

Pharma body challenges government‘s method of pricing

The government wants more time to table its new drug pricing norms. The Supreme Court has deferred hearing the matter till the 12th of December. Meanwhile, the pharma pricing policy has been challenged by the All India Drug Action Network (AIDAN).

Chemist body seek old margin in new market pricing system

Here's the latest in the hot debate over drug pricing formula. Trade body All India Organisation of Chemists and Druggists has come out in favour of the proposed market-driven pricing mechanism. But only as long as margins are not compromised, reports CNBC-TV18's Archana Shukla.

Pharma sector moots market-based pricing: Pfizer

In an interview to CNBC-TV18, Kewal Handa, managing director of Pfizer and Vikas Dandekar, India Bureau Chief of PharmAsia News.Com discuss the issue of drug pricing.